Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review.
paper
Cited
Public
Unavailable
- Authors
- Bouza, Carmen; Angeles, Magro; MuΓ±oz, Ana; Amate, JosΓ© MarΓa
- Year
- 2004
- Journal
- Addiction (Abingdon, England)
- PMID
- 15200577
- DOI
- 10.1111/j.1360-0443.2004.00763.x
AIMS: To ascertain the efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence. METHODS: Systematic review of the literature (1990-2002) and meta-analysis of full published randomized and controlled clinical trials assessing acamprosate or naltrexone therapy in alcohol dependence. Estimates of effect were calculated according to the fixed-effects model. MEASUREMENTS: Relapse and abstinence rates, cumulative abstinence duration and treatment compliance were considered as primary outcomes. Findings Thirty-three studies met the inclusion criteria. Acamprosate was associated with a significant improvement in abstinence rate [odds ratio (OR): 1.88 (1.57, 2.25), P < 0.001] and days of cumulative abstinence [WMD: 26.55 (17.56, 36.54]. Short-term administration of naltrexone reduced the relapse rate significantly [OR: 0.62 (0.52, 0.75), P < 0.001], but was not associated with a significant modification in the abstinence rate [OR: 1.26 (0.97,1.64), P = 0.08]. There were insufficient data to ascertain naltrexone's efficacy over more prolonged periods. Acamprosate had a good safety pattern and was associated with a significant improvement in treatment compliance [OR: 1.29 (1.13,1.47), P < 0.001]. Naltrexone's side effects were more numerous, yet the drug was nevertheless tolerated acceptably without being associated with a lower adherence to treatment (OR: 0.94 (0.80, 1.1), P = 0.5). However, overall compliance was relatively low with both medications. CONCLUSIONS: Both acamprosate and naltrexone are effective as adjuvant therapies for alcohol dependence in adults. Acamprosate appears to be especially useful in a therapeutic approach targeted at achieving abstinence, whereas naltrexone seems more indicated in programmes geared to controlled consumption. Both drugs are safe and acceptably tolerated but issues of compliance need to be addressed adequately to assure their usefulness in clinical practice.
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Adverse drug event profile of pharmacotherapies for alcohol use disorder: a retrospective pharmacovigilance disproportionality analysis study. | Sridharan K | β | 2026 | β |
| The Acetylcholine Esterase Inhibitor Donepezil Increases Dopamine Levels in the Nucleus Accumbens and Blocks the Alcohol Deprivation Effect in Rats. | LoftΓ©n A et al. | β | 2026 | β |
| Alcohol-Associated Hepatitis: Short- and Long-Term Management. | De La Torre SA et al. | β | 2025 | β |
| Development of Diphenyl-1,2,4-Oxadiazole Analogues as Allosteric Modulators of the RXFP3 Receptor: Evaluation of Importance of the N-Substituted-2-Pyrrolidone Moiety in RLX-33. | Guan D et al. | β | 2025 | β |
| Emergency department-initiated oral naltrexone for patients with moderate to severe alcohol use disorder: A pilot feasibility study. | Cowan E et al. | β | 2025 | β |
| Precision medicine in substance use disorders: Integrating behavioral, environmental, and biological insights. | Guerrin CGJ et al. | β | 2025 | β |
| Promising strategies for the prevention of alcohol-related brain damage through optimised management of acute alcohol withdrawal: A focussed literature review. | Quelch D et al. | β | 2025 | β |
| Psychedelic Use and Behavioral Addictions. | Brasher T et al. | β | 2025 | β |
| Alcohol does not impact chronic hepatitis C treatment outcomes but increases risk for progressive liver disease: Findings from a prospective multicentre Australian study (OPERA-C). | Clark PJ et al. | β | 2024 | β |
| Aronia Melanocarpa Elliot Anthocyanins Inhibits Alcoholic Liver Disease by Activation of Ξ±7nAChR. | Wei J et al. | β | 2024 | β |
| Association between RMTg Neuropeptide Genes and Negative Effect during Alcohol Withdrawal in Mice. | Fu Y et al. | β | 2024 | β |
| Current treatments of alcohol use disorder. | Dionisi T et al. | β | 2024 | β |
| Emergency department initiation of pharmacotherapy for alcohol use disorder: A retrospective cohort study. | De Monnin KS et al. | β | 2024 | β |
| Guidelines for Reasonable and Appropriate Care in the Emergency Department (GRACE-4): Alcohol use disorder and cannabinoid hyperemesis syndrome management in the emergency department. | Borgundvaag B et al. | β | 2024 | β |
| No Magic Pill: A Systematic Review of the Pharmacological Treatments for Compulsive Sexual Behavior Disorder. | Borgogna NC et al. | β | 2024 | β |
| Patterns of publicly funded naltrexone use among patients diagnosed with alcohol use disorder in Ontario. | Tourchian N et al. | β | 2024 | β |
| Treatment of alcohol use disorder in patients with alcohol-associated liver disease: Innovative approaches and a call to action. | Haque LY et al. | β | 2024 | β |
| Understanding Ohio X-Waivered Advanced Practice Registered Nurses' Rate of Naltrexone Prescription for Alcohol Use Disordered Patients. | Wiggins M et al. | β | 2024 | β |
| Alcohol reverses the effects of KCNJ6 (GIRK2) noncoding variants on excitability of human glutamatergic neurons. | Popova D et al. | β | 2023 | β |
| Antagonists of the stress and opioid systems restore the functional connectivity of the prefrontal cortex during alcohol withdrawal through divergent mechanisms | Carrette L et al. | β | 2023 | β |
| Efficacy of Extended-Release Injectable Naltrexone on Alcohol Use Disorder Treatment: A Systematic Review. | Kedia SK et al. | β | 2023 | β |
| Impact of policy changes and drug shortages on acamprosate and naltrexone use in Ontario, Canada. | Konstantelos N et al. | β | 2023 | β |
| Improvement of the Metabolic Stability of GPR88 Agonist RTI-13951-33: Design, Synthesis, and Biological Evaluation. | Rahman MT et al. | β | 2023 | β |
| Integration of pharmacotherapy for alcohol use disorder treatment in primary care settings: A scoping review. | Hyland CJ et al. | β | 2023 | β |
| Pharmacotherapy options for alcohol use disorder in patients with alcohol-associated liver disease: a brief guide for clinicians. | Coe C et al. | β | 2023 | β |
| Proposing an integrative, dynamic and transdiagnostic model for addictions: dysregulation phenomena of the three main modes of the predostatic mind. | Loreto BBL et al. | β | 2023 | β |
| Recurrent Mental Status Changes in a Patient With Chronic Alcoholic Cirrhosis Taking Diuretics: A Case Report. | Colalillo EA et al. | β | 2023 | β |
| Which interventions for alcohol use should be included in a universal healthcare benefit package? An umbrella review of targeted interventions to address harmful drinking and dependence. | Botwright S et al. | β | 2023 | β |
| Alcohol Use Disorder and Alcohol-Associated Liver Disease. | Ramkissoon R et al. | β | 2022 | β |
| Alcohol use disorder pharmacotherapy and treatment in primary care (ADaPT-PC) trial: Impact on identified barriers to implementation. | Hagedorn HJ et al. | β | 2022 | β |
| Eosinophilic pustular folliculitis due to naltrexone: A case report. | Smith SS et al. | β | 2022 | β |
| Incidence and Progression of Alcohol-Associated Liver Disease After Medical Therapy for Alcohol Use Disorder. | Vannier AGL et al. | β | 2022 | β |
| Naltrexone for alcohol use disorder: Hepatic safety in patients with and without liver disease. | Ayyala D et al. | β | 2022 | β |
| Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder. | Burnette EM et al. | β | 2022 | β |
| Tolerability and efficacy of paroxetine and naltrexone for treatment of compulsive sexual behaviour disorder. | Lew-Starowicz M et al. | β | 2022 | β |
| Complement System in Alcohol-Associated Liver Disease. | Santiesteban-Lores LE et al. | β | 2021 | β |
| Diversity inclusion in United States opioid pharmacological treatment trials: A systematic review. | Nalven T et al. | β | 2021 | β |
| Genetic contributions to alcohol use disorder treatment outcomes: a genome-wide pharmacogenomics study. | Biernacka JM et al. | β | 2021 | β |
| Multifactorial Basis and Therapeutic Strategies in Metabolism-Related Diseases. | Guerra JVS et al. | β | 2021 | β |
| Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studies. | Andersen KAA et al. | β | 2021 | β |
| Therapeutic potential of ketamine for alcohol use disorder. | Worrell SD et al. | β | 2021 | β |
| A novel human laboratory model for screening medications for alcohol use disorder. | Ho D et al. | β | 2020 | β |
| Availability of Medications for the Treatment of Alcohol and Opioid Use Disorder in the USA. | Abraham AJ et al. | β | 2020 | β |
| Behavioral and neural processes in counterconditioning: Past and future directions. | Keller NE et al. | β | 2020 | β |
| Community-based psychosocial substance use disorder interventions in low-and-middle-income countries: a narrative literature review. | Heijdra Suasnabar JM et al. | β | 2020 | β |
| Correlates of alcohol use disorder pharmacotherapy receipt in medically insured patients. | Rittenberg A et al. | β | 2020 | β |
| Ethanol induces maladaptive impulse control and decreased seeking behaviors in mice. | Starski P et al. | β | 2020 | β |
| Gabapentin for Post-Hospitalization Alcohol Relapse Prevention; Should Gabapentin Be Considered for FDA Approval in the Treatment of Alcohol Use Disorder?: A Case Presentation and Literature Review. | Rutkofsky IH et al. | β | 2020 | β |
| Naltrexone Use in Treating Hypersexuality Induced by Dopamine Replacement Therapy: Impact of <i>OPRM1</i> A/G Polymorphism on Its Effectiveness. | Verholleman A et al. | β | 2020 | β |
| Pharmacotherapeutic management of co-morbid alcohol and opioid use. | Hood LE et al. | β | 2020 | β |
| Pharmacotherapies and personalized medicine for alcohol use disorder: a review. | Lohoff FW | β | 2020 | β |
| Applications of <i>Pueraria lobata</i> in treating diabetics and reducing alcohol drinking. | Liu J et al. | β | 2019 | β |
| Association Study of OPRM1 Gene in a Sample of Schizophrenia Patients With Alcohol Dependence or Abuse. | Gendy MNS et al. | β | 2019 | β |
| Building better strategies to develop new medications in Alcohol Use Disorder: Learning from past success and failure to shape a brighter future. | Cannella N et al. | β | 2019 | β |
| Cessation and reduction in alcohol consumption and misuse after psychedelic use. | Garcia-Romeu A et al. | β | 2019 | β |
| Dopamine and opioid systems adaptation in alcoholism revisited: Convergent evidence from positron emission tomography and postmortem studies. | Hansson AC et al. | β | 2019 | β |
| GDNF and alcohol use disorder. | Barak S et al. | β | 2019 | β |
| Implementing alcohol use disorder pharmacotherapy in primary care settings: a qualitative analysis of provider-identified barriers and impact on implementation outcomes. | Hagedorn HJ et al. | β | 2019 | β |
| Pharmacogenetics of alcohol addiction: current perspectives. | Zastrozhin MS et al. | β | 2019 | β |
| Receipt of pharmacotherapy for alcohol use disorder by justice-involved women in the Veterans Health Administration. | Taylor E et al. | β | 2019 | β |
| Reward, Relief and Habit Drinking: Initial Validation of a Brief Assessment Tool. | Grodin EN et al. | β | 2019 | β |
| State-of-the-art behavioral and pharmacological treatments for alcohol use disorder. | Ray LA et al. | β | 2019 | β |
| Alcohol Use in Patients with Chronic Liver Disease. | Fuster D et al. | β | 2018 | β |
| An Overview of Pharmacotherapy Options for Alcohol Use Disorder. | Carpenter JE et al. | β | 2018 | β |
| Associations of alcohol use disorder, alcohol use, housing, and service use in a homeless sample of 255 individuals followed over 2 years. | Asana OO et al. | β | 2018 | β |
| Discovery of a Potent, Selective, and Brain-Penetrant Small Molecule that Activates the Orphan Receptor GPR88 and Reduces Alcohol Intake. | Jin C et al. | β | 2018 | β |
| Extended-release naltrexone and drug treatment courts: Policy and evidence for implementing an evidence-based treatment. | Robertson AG et al. | β | 2018 | β |
| Mining the nucleus accumbens proteome for novel targets of alcohol self-administration in male C57BL/6J mice. | Faccidomo S et al. | β | 2018 | β |
| Naltrexone ameliorates functional network abnormalities in alcohol-dependent individuals. | Morris LS et al. | β | 2018 | β |
| Pharmacotherapy for relapse prevention of alcohol use disorder in the Indian setting: A systematic review. | Bharadwaj B et al. | β | 2018 | β |
| Preclinical evaluation of avermectins as novel therapeutic agents for alcohol use disorders. | Khoja S et al. | β | 2018 | β |
| Predictors of Daily Adherence to Naltrexone for Alcohol Use Disorder Treatment During a Mobile Health Intervention. | Dermody SS et al. | β | 2018 | β |
| Receipt of Pharmacotherapy for Alcohol Use Disorder by Male Justice-Involved U.S. Veterans Health Administration Patients. | Finlay AK et al. | β | 2018 | β |
| Study protocol: a cluster-randomized trial implementing Sustained Patient-centered Alcohol-related Care (SPARC trial). | Glass JE et al. | β | 2018 | β |
| Substance Use Disorders Among Veterans in a Nationally Representative Sample: Prevalence and Associated Functioning and Treatment Utilization. | Boden MT et al. | β | 2018 | β |
| The Black Book of Psychotropic Dosing and Monitoring. | Schatzberg AF et al. | β | 2018 | β |
| A Systematic Review of Naltrexone for Attenuating Alcohol Consumption in Women with Alcohol Use Disorders. | Canidate SS et al. | β | 2017 | β |
| Circuit and synaptic mechanisms of repeated stress: Perspectives from differing contexts, duration, and development. | Bath KG et al. | β | 2017 | β |
| Cue exposure therapy for the treatment of alcohol use disorders: A meta-analytic review. | Mellentin AI et al. | β | 2017 | β |
| Evaluation of a Pilot Implementation to Integrate Alcohol-Related Care within Primary Care. | Bobb JF et al. | β | 2017 | β |
| Extended-release naltrexone reduces alcohol consumption among released prisoners with HIV disease as they transition to the community. | Springer SA et al. | β | 2017 | β |
| First-line medications for alcohol use disorders among public drug plan beneficiaries in Ontario. | Spithoff S et al. | β | 2017 | β |
| Management of alcohol misuse in patients with liver diseases. | Peng JL et al. | β | 2017 | β |
| Mechanical Stimulation of the HT7 Acupuncture Point to Reduce Ethanol Self-Administration in Rats. | Kang SY et al. | β | 2017 | β |
| Naltrexone for the treatment of comorbid tobacco and pornography addiction. | Capurso NA | β | 2017 | β |
| Randomized open-label trial of baclofen for relapse prevention in alcohol dependence. | Gupta M et al. | β | 2017 | β |
| The Impact of Mobile Apps on Alcohol Use Disorder: A Systematic Review Protocol. | Sawares AS et al. | β | 2017 | β |
| Therapeutic interventions for alcohol dependence in non-inpatient settings: a systematic review and network meta-analysis (protocol). | Cheng HY et al. | β | 2017 | β |
| The Role of the Melanocortin System in Drug and Alcohol Abuse. | Navarro M | β | 2017 | β |
| The safety and efficacy of baclofen to reduce alcohol use in veterans with chronic hepatitis C: a randomized controlled trial. | Hauser P et al. | β | 2017 | β |
| Varenicline Reduces Alcohol Intake During Repeated Cycles of Alcohol Reaccess Following Deprivation in Alcohol-Preferring (P) Rats. | Froehlich JC et al. | β | 2017 | β |
| Zero-inflated count models for longitudinal measurements with heterogeneous random effects. | Zhu H et al. | β | 2017 | β |
| Alcohol addiction and the mu-opioid receptor. | Berrettini W | β | 2016 | β |
| Enhancing access to alcohol use disorder pharmacotherapy and treatment in primary care settings: ADaPT-PC. | Hagedorn HJ et al. | β | 2016 | β |
| Gender differences in treatment and clinical characteristics among patients receiving extended release naltrexone. | Herbeck DM et al. | β | 2016 | β |
| In the Clinic. Substance Use Disorders. | Pace CA et al. | β | 2016 | β |
| Mu-opioid receptor activation in the medial shell of nucleus accumbens promotes alcohol consumption, self-administration and cue-induced reinstatement. | Richard JM et al. | β | 2016 | β |
| Opioid neuroscience for addiction medicine: From animal models to FDA approval for alcohol addiction. | Berrettini W | β | 2016 | β |
| Optimal management for alcoholic liver disease: Conventional medications, natural therapy or combination? | Kim MS et al. | β | 2016 | β |
| Pharmacotherapy for Alcohol Dependence: The 2015 Recommendations of the French Alcohol Society, Issued in Partnership with the European Federation of Addiction Societies. | Rolland B et al. | β | 2016 | β |
| Smoking Cessation and Adolescent Treatment Response With Comorbid ADHD. | Pagano ME et al. | β | 2016 | β |
| Subjective Response to Alcohol as a Research Domain Criterion. | Ray LA et al. | β | 2016 | β |
| The BDNF Valine 68 to Methionine Polymorphism Increases Compulsive Alcohol Drinking in Mice That Is Reversed by Tropomyosin Receptor Kinase B Activation. | Warnault V et al. | β | 2016 | β |
| The Diffusion of Acamprosate for the Treatment of Alcohol Use Disorder: Results From a National Longitudinal Study. | Knudsen HK et al. | β | 2016 | β |
| The impact of treatment condition and the lagged effects of PTSD symptom severity and alcohol use on changes in alcohol craving. | Kaczkurkin AN et al. | β | 2016 | β |
| The Role of Pharmacotherapy in the Treatment of Adolescent Substance Use Disorders. | Hammond CJ | β | 2016 | β |
| Addiction pharmacogenetics: a systematic review of the genetic variation of the dopaminergic system. | Patriquin MA et al. | β | 2015 | β |
| Adoption of injectable naltrexone in U.S. substance use disorder treatment programs. | Aletraris L et al. | β | 2015 | β |
| Alcohol liver disease: A review of current therapeutic approaches to achieve long-term abstinence. | GarcΓa ML et al. | β | 2015 | β |
| A pharmacogenetic determinant of mu-opioid receptor antagonist effects on alcohol reward and consumption: evidence from humanized mice. | Bilbao A et al. | β | 2015 | β |
| Breaking the addictive cycle of the system: improving US criminal justice practices to address substance use disorders. | Kopak AM | β | 2015 | β |
| Combined administration of buprenorphine and naltrexone produces antidepressant-like effects in mice. | Almatroudi A et al. | β | 2015 | β |
| Extended-release naltrexone and harm reduction counseling for chronically homeless people with alcohol dependence. | Collins SE et al. | β | 2015 | β |
| Impact of binge alcohol on mortality among people who inject drugs. | Johnson C et al. | β | 2015 | β |
| Pharmacogenetics of alcohol use disorders and comorbid psychiatric disorders. | Helton SG et al. | β | 2015 | β |
| Pharmacotherapy for alcohol dependence: A stratified approach. | Thompson A et al. | β | 2015 | β |
| A Bayesian mixed-treatment comparison meta-analysis of treatments for alcohol dependence and implications for planning future trials. | DeSantis SM et al. | β | 2014 | β |
| Acamprosate-induced Extrapyramidal Symptoms in an Elderly Patient with Alcohol Dependence. | Woo J et al. | β | 2014 | β |
| Alcohol use disorder: pathophysiology, effects, and pharmacologic options for treatment. | Wackernah RC et al. | β | 2014 | β |
| Alcohol use disorders and current pharmacological therapies: the role of GABA(A) receptors. | Liang J et al. | β | 2014 | β |
| A randomized clinical trial of alcohol care management delivered in Department of Veterans Affairs primary care clinics versus specialty addiction treatment. | Oslin DW et al. | β | 2014 | β |
| Baclofen-induced edema in alcohol use disorders. | Bence C et al. | β | 2014 | β |
| Clinical and biological moderators of response to naltrexone in alcohol dependence: a systematic review of the evidence. | Garbutt JC et al. | β | 2014 | β |
| Dissemination, adoption, and implementation of acamprosate for treating alcohol use disorders. | Knudsen HK et al. | β | 2014 | β |
| Drug effects on multiple and concurrent schedules of ethanol- and food-maintained behaviour: context-dependent selectivity. | Ginsburg BC et al. | β | 2014 | β |
| Effects of systemic opioid receptor ligands on ethanol- and sucrose seeking and drinking in alcohol-preferring (P) and Long Evans rats. | Henderson-Redmond A et al. | β | 2014 | β |
| Genetic markers associated with abstinence length in alcohol-dependent subjects treated with acamprosate. | Karpyak VM et al. | β | 2014 | β |
| Inhibition of phosphodiesterase 4 reduces ethanol intake and preference in C57BL/6J mice. | Blednov YA et al. | β | 2014 | β |
| Long-acting injectable depot naltrexone use in the Veterans' Health Administration: a national study. | Marienfeld C et al. | β | 2014 | β |
| Outcome predictors for problem drinkers treated with combined cognitive behavioral therapy and naltrexone. | Vuoristo-Myllys S et al. | β | 2014 | β |
| Pharmacologic treatment of alcoholism. | Anton RF et al. | β | 2014 | β |
| Pharmacotherapy of alcohol use disorders: seventy-five years of progress. | Zindel LR et al. | β | 2014 | β |
| Potent inhibition of alcohol self-administration in alcohol-preferring rats by a ΞΊ-opioid receptor antagonist. | Cashman JR et al. | β | 2014 | β |
| Preventive Effects of Forced Exercise against Alcohol-induced Physical Dependency and Reduction of Pain Perception Threshold. | Motaghinejad M et al. | β | 2014 | β |
| Reduction of excessive alcohol drinking by a novel GABAB receptor positive allosteric modulator ADX71441 in mice. | Hwa LS et al. | β | 2014 | β |
| Substance abuse/dependence treatment: a European perspective. | Metz VE et al. | β | 2014 | β |
| Targeting central melanocortin receptors: a promising novel approach for treating alcohol abuse disorders. | Olney JJ et al. | β | 2014 | β |
| The clinical pharmacology of acamprosate. | Kalk NJ et al. | β | 2014 | β |
| Acamprosate suppresses ethanol-induced place preference in mice with ethanol physical dependence. | Kurokawa K et al. | β | 2013 | β |
| Chromatin remodeling: a new landscape to treat harmful alcohol-use disorders. | Warnault V et al. | β | 2013 | β |
| Chromatin remodeling--a novel strategy to control excessive alcohol drinking. | Warnault V et al. | β | 2013 | β |
| Chronic care management for dependence on alcohol and other drugs: the AHEAD randomized trial. | Saitz R et al. | β | 2013 | β |
| Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. | Hollander P et al. | β | 2013 | β |
| Extended-release naltrexone (XR-NTX) attenuates brain responses to alcohol cues in alcohol-dependent volunteers: a bold FMRI study. | Lukas SE et al. | β | 2013 | β |
| Green tea extract co-administered with a polymer effectively prevents alcoholic liver damage by prolonged inhibition of alcohol absorption in mice. | Park JH et al. | β | 2013 | β |
| Improving clinical outcomes for naltrexone as a management of problem alcohol use. | Hulse GK | β | 2013 | β |
| KASL clinical practice guidelines: management of alcoholic liver disease. | Korean Association for the Study of the Liver (KASL) | β | 2013 | β |
| Management of alcohol dependence in patients with liver disease. | Addolorato G et al. | β | 2013 | β |
| Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful? | Maisel NC et al. | β | 2013 | β |
| Naltrexone (50 mg) plus psychotherapy in alcohol-dependent patients: a meta-analysis of randomized controlled trials. | Jarosz J et al. | β | 2013 | β |
| Opioid pharmacogenetics of alcohol addiction. | Berrettini W | β | 2013 | β |
| Pharmacotherapy for alcohol dependence: status of current treatments. | Franck J et al. | β | 2013 | β |
| Placebo group improvement in trials of pharmacotherapies for alcohol use disorders: a multivariate meta-analysis examining change over time. | Del Re AC et al. | β | 2013 | β |
| Recent advances in the discovery and preclinical testing of novel compounds for the prevention and/or treatment of alcohol use disorders. | Davies DL et al. | β | 2013 | β |
| Relaxin-3/RXFP3 system regulates alcohol-seeking. | Ryan PJ et al. | β | 2013 | β |
| Safety and efficacy of acamprosate for the treatment of alcohol dependence. | Yahn SL et al. | β | 2013 | β |
| The Grog Mob: lessons from an evaluation of a multi-disciplinary alcohol intervention for Aboriginal clients. | d'Abbs P et al. | β | 2013 | β |
| The ΞΌ-opioid receptor and treatment response to naltrexone. | Thorsell A | β | 2013 | β |
| ΞΌ-Opioid receptor gene (OPRM1) polymorphism A118G: lack of association in Finnish populations with alcohol dependence or alcohol consumption. | Rouvinen-LagerstrΓΆm N et al. | β | 2013 | β |
| Acamprosate for treatment of alcohol dependence: mechanisms, efficacy, and clinical utility. | Witkiewitz K et al. | β | 2012 | β |
| Alcohol consumption induces endogenous opioid release in the human orbitofrontal cortex and nucleus accumbens. | Mitchell JM et al. | β | 2012 | β |
| A mixed non-homogeneous hidden Markov model for categorical data, with application to alcohol consumption. | Maruotti A et al. | β | 2012 | β |
| Association of Β΅-opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta-analysis. | Chamorro AJ et al. | β | 2012 | β |
| BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP. | Lingford-Hughes AR et al. | β | 2012 | β |
| [Clinical alcohology]. | Cottencin O et al. | β | 2012 | β |
| Current progress in pharmacologic treatment strategies for alcohol dependence. | Clapp P | β | 2012 | β |
| Do placebo response rates from cessation trials inform on strength of addictions? | Moore RA et al. | β | 2012 | β |
| Effects of naltrexone on alcohol drinking patterns and extinction of alcohol seeking in baboons. | Kaminski BJ et al. | β | 2012 | β |
| Long-term management of alcoholic liver disease. | Woo GA et al. | β | 2012 | β |
| Mu opioid receptor (OPRM1) as a predictor of treatment outcome in opiate-dependent individuals of Arab descent. | Al-Eitan LN et al. | β | 2012 | β |
| Personalized treatment of alcohol dependence. | Kranzler HR et al. | β | 2012 | β |
| Reduced alcohol intake and reward associated with impaired endocannabinoid signaling in mice with a deletion of the glutamate transporter GLAST. | Karlsson RM et al. | β | 2012 | β |
| Review of biological mechanisms and pharmacological treatments of comorbid PTSD and substance use disorder. | Norman SB et al. | β | 2012 | β |
| Sleep disturbance in alcoholism: proposal of a simple measurement, and results from a 24-week randomized controlled study of alcohol-dependent patients assessing acamprosate efficacy. | Perney P et al. | β | 2012 | β |
| The anticonvulsant levetiracetam potentiates alcohol consumption in non-treatment seeking alcohol abusers. | Mitchell JM et al. | β | 2012 | β |
| The cost-effectiveness of tailored, postal feedback on general practitioners' prescribing of pharmacotherapies for alcohol dependence. | Navarro HJ et al. | β | 2012 | β |
| The neurobiology of binge-like ethanol drinking: evidence from rodent models. | Sprow GM et al. | β | 2012 | β |
| Varenicline decreases alcohol consumption in heavy-drinking smokers. | Mitchell JM et al. | β | 2012 | β |
| Adherence monitoring in naltrexone pharmacotherapy trials: a systematic review. | Swift R et al. | β | 2011 | β |
| A genetic determinant of the striatal dopamine response to alcohol in men. | Ramchandani VA et al. | β | 2011 | β |
| Alcohol and the human brain: a systematic review of different neuroimaging methods. | BΓΌhler M et al. | β | 2011 | β |
| A literature review of cost-benefit analyses for the treatment of alcohol dependence. | Popova S et al. | β | 2011 | β |
| A longitudinal examination of alcohol pharmacotherapy adoption in substance use disorder treatment programs: patterns of sustainability and discontinuation. | Abraham AJ et al. | β | 2011 | β |
| Barriers to use of pharmacotherapy for addiction disorders and how to overcome them. | Oliva EM et al. | β | 2011 | β |
| Chronic alcohol neuroadaptation and stress contribute to susceptibility for alcohol craving and relapse. | Breese GR et al. | β | 2011 | β |
| Clinical experience with baclofen in the management of alcohol-dependent patients with psychiatric comorbidity: a selected case series. | Dore GM et al. | β | 2011 | β |
| Counselor attitudes toward the use of naltrexone in substance abuse treatment: a multi-level modeling approach. | Abraham AJ et al. | β | 2011 | β |
| Critical thoughts on current rodent models for evaluating potential treatments of alcohol addiction and withdrawal. | Ripley TL et al. | β | 2011 | β |
| Efficacy of extended-release naltrexone in patients with relatively higher severity of alcohol dependence. | Pettinati HM et al. | β | 2011 | β |
| Intramuscular extended-release naltrexone: current evidence. | Gastfriend DR | β | 2011 | β |
| Opioid modulators for alcohol dependence. | Hillemacher T et al. | β | 2011 | β |
| Pharmacogenetic approaches to the treatment of alcohol addiction. | Heilig M et al. | β | 2011 | β |
| Safety, tolerability, and feasibility of high-dose naltrexone in alcohol dependence: an open-label study. | Yoon G et al. | β | 2011 | β |
| Selective blockade of the orexin-2 receptor attenuates ethanol self-administration, place preference, and reinstatement. | Shoblock JR et al. | β | 2011 | β |
| Supervised disulfiram in the treatment of alcohol use disorder: a commentary. | Krampe H et al. | β | 2011 | β |
| The effect of naltrexone on alcohol's stimulant properties and self-administration behavior in social drinkers: influence of gender and genotype. | Setiawan E et al. | β | 2011 | β |
| The efficacy of disulfiram for the treatment of alcohol use disorder. | JΓΈrgensen CH et al. | β | 2011 | β |
| Treating alcoholism as a chronic disease: approaches to long-term continuing care. | McKay JR et al. | β | 2011 | β |
| Treatment of alcoholic liver disease. | Frazier TH et al. | β | 2011 | β |
| Acamprosate: a prototypic neuromodulator in the treatment of alcohol dependence. | Mason BJ et al. | β | 2010 | β |
| Acamprosate for alcohol dependence. | RΓΆsner S et al. | β | 2010 | β |
| [A system of prescriptions without drug approval: example of baclofen]. | Rolland B et al. | β | 2010 | β |
| Bioavailability in vivo of naltrexone following transbuccal administration by an electronically-controlled intraoral device: a trial on pigs. | Campisi G et al. | β | 2010 | β |
| Biological and psychological interventions: trends in substance use disorders intervention research. | Wessell R et al. | β | 2010 | β |
| Comparison of healthcare utilization among patients treated with alcoholism medications. | Mark TL et al. | β | 2010 | β |
| Effect of early and late compliance on the effectiveness of acamprosate in the treatment of alcohol dependence. | Koeter MW et al. | β | 2010 | β |
| Emerging drugs to treat alcoholism. | Soyka M et al. | β | 2010 | β |
| Genetic variation and brain gene expression in rodent models of alcoholism implications for medication development. | BjΓΆrk K et al. | β | 2010 | β |
| Integrated Management of Physician-delivered Alcohol Care for Tuberculosis Patients: Design and Implementation. | Greenfield SF et al. | β | 2010 | β |
| Opioid antagonists for alcohol dependence. | RΓΆsner S et al. | β | 2010 | β |
| Pharmacogenetics of alcohol and alcohol dependence treatment. | Kranzler HR et al. | β | 2010 | β |
| Pharmacologic dissociation between impulsivity and alcohol drinking in high alcohol preferring mice. | Oberlin BG et al. | β | 2010 | β |
| Suppression of alcohol preference by naltrexone in the rhesus macaque: a critical role of genetic variation at the micro-opioid receptor gene locus. | Barr CS et al. | β | 2010 | β |
| Suppression of alcohol self-administration and reinstatement of alcohol seeking by melanin-concentrating hormone receptor 1 (MCH1-R) antagonism in Wistar rats. | Cippitelli A et al. | β | 2010 | β |
| The effects of current subsyndromal psychiatric symptoms or past psychopathology on alcohol dependence treatment outcomes and acamprosate efficacy. | Mason BJ et al. | β | 2010 | β |
| The Effects of Naltrexone Among Alcohol Non-Abstainers: Results from the COMBINE Study. | Ray LA et al. | β | 2010 | β |
| The neurobiology, clinical efficacy and safety of acamprosate in the treatment of alcohol dependence. | Mason BJ et al. | β | 2010 | β |
| The past and future of research on treatment of alcohol dependence. | Willenbring ML | β | 2010 | β |
| The performance of the Alcohol Use Disorder Identification Test (AUDIT) in detecting alcohol abuse and dependence in a population of depressed or anxious persons. | Boschloo L et al. | β | 2010 | β |
| The pharmacotherapy of alcohol dependence: a state of the art review. | De Sousa A | β | 2010 | β |
| Translating the neuroscience of alcoholism into clinical treatments: from blocking the buzz to curing the blues. | Heilig M et al. | β | 2010 | β |
| Why is disulfiram superior to acamprosate in the routine clinical setting? A retrospective long-term study in 353 alcohol-dependent patients. | Diehl A et al. | β | 2010 | β |
| Acamprosate and naltrexone treatment effects on ethanol and sucrose seeking and intake in ethanol-dependent and nondependent rats. | Czachowski CL et al. | β | 2009 | β |
| Acupuncture for alcohol dependence: a systematic review. | Cho SH et al. | β | 2009 | β |
| Acute interaction of baclofen in combination with alcohol in heavy social drinkers. | Evans SM et al. | β | 2009 | β |
| Alcohol-related absenteeism: the need to analyse consumption patterns in order to target screening and brief interventions in the workplace. | Leggat PA et al. | β | 2009 | β |
| Cabergoline decreases alcohol drinking and seeking behaviors via glial cell line-derived neurotrophic factor. | Carnicella S et al. | β | 2009 | β |
| Effect of extended-release naltrexone (XR-NTX) on quality of life in alcohol-dependent patients. | Pettinati HM et al. | β | 2009 | β |
| Effects of nicotine and illicit substance use on alcoholism treatment outcomes and acamprosate efficacy. | Mason BJ et al. | β | 2009 | β |
| Naltrexone aversion and treatment efficacy are greatest in humans and rats that actively consume high levels of alcohol. | Mitchell JM et al. | β | 2009 | β |
| Naltrexone decreases heavy drinking rates in smoking cessation treatment: an exploratory study. | King A et al. | β | 2009 | β |
| Packages of care for alcohol use disorders in low- and middle-income countries. | Benegal V et al. | β | 2009 | β |
| Rational design of a combination medication for the treatment of obesity. | Greenway FL et al. | β | 2009 | β |
| Sweet liking phenotype, alcohol craving and response to naltrexone treatment in alcohol dependence. | Garbutt JC et al. | β | 2009 | β |
| Synthesis and pharmacological evaluation of 6-naltrexamine analogs for alcohol cessation. | Ghirmai S et al. | β | 2009 | β |
| Targeted naltrexone for problem drinkers. | Kranzler HR et al. | β | 2009 | β |
| The cost effectiveness of naltrexone added to cognitive-behavioral therapy in the treatment of alcohol dependence. | Walters D et al. | β | 2009 | β |
| Understanding attitudes towards use of medication in substance abuse treatment: A multilevel approach. | Fitzgerald JP et al. | β | 2009 | β |
| Acamprosate efficacy in alcohol-dependent patients: summary of results from three pivotal trials. | Kranzler HR et al. | β | 2008 | β |
| Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes. | RΓΆsner S et al. | β | 2008 | β |
| [Alcohol dependence: diagnosis and treatment]. | Perney P et al. | β | 2008 | β |
| An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. | Anton RF et al. | β | 2008 | β |
| A placebo-controlled randomized clinical trial of naltrexone in the context of different levels of psychosocial intervention. | Oslin DW et al. | β | 2008 | β |
| A randomized, multicentre, open-label, comparative trial of disulfiram, naltrexone and acamprosate in the treatment of alcohol dependence. | Laaksonen E et al. | β | 2008 | β |
| Comparing topiramate with naltrexone in the treatment of alcohol dependence. | Baltieri DA et al. | β | 2008 | β |
| Do acamprosate or naltrexone have an effect on daily drinking by reducing craving for alcohol? | Richardson K et al. | β | 2008 | β |
| Effect of chronic acamprosate treatment on voluntary alcohol intake and beta-endorphin plasma levels in rats selectively bred for high alcohol preference. | Zalewska-Kaszubska J et al. | β | 2008 | β |
| Gender differences in predictors of treatment attrition with high dose naltrexone in cocaine and alcohol dependence. | Suh JJ et al. | β | 2008 | β |
| Genetic basis for predicting response to naltrexone in the treatment of alcohol dependence. | Anton RF | β | 2008 | β |
| Glutamatergic dysfunction in schizophrenia: from basic neuroscience to clinical psychopharmacology. | Paz RD et al. | β | 2008 | β |
| Glutamatergic substrates of drug addiction and alcoholism. | Gass JT et al. | β | 2008 | β |
| Hepatic safety of once-monthly injectable extended-release naltrexone administered to actively drinking alcoholics. | Lucey MR et al. | β | 2008 | β |
| Impact of socio-psychological factors on treatment adherence of TB patients in Russia. | Jakubowiak WM et al. | β | 2008 | β |
| Improving acceptance of naltrexone in community addiction treatment centers: a pilot study. | Thomas SE et al. | β | 2008 | β |
| Moderators of naltrexone's effects on drinking, urge, and alcohol effects in non-treatment-seeking heavy drinkers in the natural environment. | Tidey JW et al. | β | 2008 | β |
| Naltrexone and cognitive behavioral therapy for the treatment of alcohol dependence: do sex differences exist? | Baros AM et al. | β | 2008 | β |
| Naltrexone for the management of alcohol dependence. | Anton RF | β | 2008 | β |
| Synthesis and biological evaluation of alpha- and beta-6-amido derivatives of 17-cyclopropylmethyl-3, 14beta-dihydroxy-4, 5alpha-epoxymorphinan: potential alcohol-cessation agents. | Ghirmai S et al. | β | 2008 | β |
| The effects of maternally administered methadone, buprenorphine and naltrexone on offspring: review of human and animal data. | Farid WO et al. | β | 2008 | β |
| Topiramate for alcohol dependence. | Olmsted CL et al. | β | 2008 | β |
| Treatment implications: using neuroscience to guide the development of new pharmacotherapies for alcoholism. | Krishnan-Sarin S et al. | β | 2008 | β |
| Treatment of co-occurring alcohol and other drug use disorders. | Arias AJ et al. | β | 2008 | β |
| Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings. | Johnson BA | β | 2008 | β |
| World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Substance Use and Related Disorders, Part 1: Alcoholism. | Soyka M et al. | β | 2008 | β |
| Acamprosate in alcohol dependence: implications of a unique mechanism of action. | Littleton JM | β | 2007 | β |
| Acamprosate in the treatment of alcohol dependence: clinical and economic considerations. | Mason BJ et al. | β | 2007 | β |
| A functional polymorphism of the mu-opioid receptor gene (OPRM1) influences cue-induced craving for alcohol in male heavy drinkers. | van den Wildenberg E et al. | β | 2007 | β |
| Buprenorphine reduces alcohol drinking through activation of the nociceptin/orphanin FQ-NOP receptor system. | Ciccocioppo R et al. | β | 2007 | β |
| Efficacy and tolerability of naltrexone in the treatment of alcohol dependence: oral versus injectable delivery. | Roozen HG et al. | β | 2007 | β |
| Efficacy of extended-release naltrexone in alcohol-dependent patients who are abstinent before treatment. | O'Malley SS et al. | β | 2007 | β |
| Herbal mixtures consisting of puerarin and either polyenylphosphatidylcholine or curcumin provide comprehensive protection against alcohol-related disorders in P rats receiving free choice water and 15% ethanol in pure water. | Singh AK et al. | β | 2007 | β |
| Long-acting injectable naltrexone for the treatment of alcohol dependence. | Mannelli P et al. | β | 2007 | β |
| Mu (mu) opioid receptor regulation of ethanol-induced dopamine response in the ventral striatum: evidence of genotype specific sexual dimorphic epistasis. | Job MO et al. | β | 2007 | β |
| Naltrexone increased abstinence and reduced heavy drinking during treatment. | Bradley K | β | 2007 | β |
| New insights into the efficacy of naltrexone based on trajectory-based reanalyses of two negative clinical trials. | Gueorguieva R et al. | β | 2007 | β |
| Outpatient Long-term Intensive Therapy for Alcoholics (OLITA): a successful biopsychosocial approach to the treatment of alcoholism. | Krampe H et al. | β | 2007 | β |
| Pharmacoprophylaxis of alcohol dependence: Review and update Part II: Efficacy. | Grover S et al. | β | 2007 | β |
| Polymorphisms in the mu-opioid receptor gene (OPRM1) and the implications for alcohol dependence in humans. | van der Zwaluw CS et al. | β | 2007 | β |
| Preclinical and clinical pharmacology of alcohol dependence. | Tambour S et al. | β | 2007 | β |
| Release of naltrexone on buccal mucosa: permeation studies, histological aspects and matrix system design. | Giannola LI et al. | β | 2007 | β |
| The treatment of alcohol dependence. | Assanangkornchai S et al. | β | 2007 | β |
| Treatment of alcohol and other drug dependence. | Saitz R | β | 2007 | β |
| Acamprosate: a new tool in the battle against alcohol dependence. | Wright TM et al. | β | 2006 | β |
| A systematic review of the effectiveness of naltrexone in the maintenance treatment of opioid and alcohol dependence. | Roozen HG et al. | β | 2006 | β |
| Development of a mouse model of ethanol addiction: naltrexone efficacy in reducing consumption but not craving. | Fachin-Scheit DJ et al. | β | 2006 | β |
| Effect of oral naltrexone on pruritus in cholestatic patients. | Mansour-Ghanaei F et al. | β | 2006 | β |
| Is acamprosate use in alcohol dependence treatment reflected in improved subjective health status outcomes beyond cognitive behavioural therapy alone?. | Feeney GF et al. | β | 2006 | β |
| Medications to treat heavy drinking: are we there yet? | Kranzler H | β | 2006 | β |
| Naltrexone versus acamprosate in the treatment of alcohol dependence: A multi-centre, randomized, double-blind, placebo-controlled trial. | Morley KC et al. | β | 2006 | β |
| New pharmacological approaches for the treatment of alcoholism. | Soyka M et al. | β | 2006 | β |
| Schedule-induced alcohol drinking: non-selective effects of acamprosate and naltrexone. | Escher T et al. | β | 2006 | β |
| Social factors but not stress-coping styles predict relapse in detoxified alcoholics. | Walter M et al. | β | 2006 | β |
| The alcohol-preferring AA and alcohol-avoiding ANA rats: neurobiology of the regulation of alcohol drinking. | Sommer W et al. | β | 2006 | β |
| The status of disulfiram: a half of a century later. | Suh JJ et al. | β | 2006 | β |
| Use of pharmacotherapies for the management of addictive behaviours in Australian clinical practice. | Doran CM et al. | β | 2006 | β |
| Acamprosate: a review of its use in the maintenance of abstinence in patients with alcohol dependence. | Scott LJ et al. | β | 2005 | β |
| Acamprosate for the treatment of alcohol dependence. | Boothby LA et al. | β | 2005 | β |
| Acamprosate in the treatment of alcohol dependence. | Mason BJ | β | 2005 | β |
| Clinical practice. Unhealthy alcohol use. | Saitz R | β | 2005 | β |
| Development of medications for alcohol use disorders: recent advances and ongoing challenges. | Litten RZ et al. | β | 2005 | β |
| Does effect size in naltrexone trials for alcohol dependence differ for single-site vs. multi-center studies? | Feinn R et al. | β | 2005 | β |
| Effect of natural and synthetic polyamines on ethanol intake in UChB drinker rats. | Bilbeny N et al. | β | 2005 | β |
| Integrating care for patients with infectious, psychiatric, and substance use disorders: concepts and approaches. | Willenbring ML | β | 2005 | β |
| Natural medicines for alcoholism treatment: a review. | Xu BJ et al. | β | 2005 | β |
| Novel pharmacotherapeutic targets for the management of drug addiction. | Heidbreder C | β | 2005 | β |
| Review: acamprosate and naltrexone are safe and effective but have low compliance rates for people with alcohol dependence. | Feeney GF et al. | β | 2005 | β |
| The contribution of genetics to addiction therapy approaches. | Edenberg HJ et al. | β | 2005 | β |
| Acamprosate for alcohol dependence? | β | β | 1997 | β |